Screener
Aspen Aerogels ASPN Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Aspen Aerogels in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: Aspen Aerogels’s 10-Q, filed August 7, 2026. Open the filing →
- Filed
- Aug 7, 2026, 4:15 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-340275
FAQ
- What is Aspen Aerogels's cash & equivalents?
- Aspen Aerogels (ASPN) reported cash & equivalents of $151.71M in Q2 2026.
- How has Aspen Aerogels's cash & equivalents changed year-over-year?
- Aspen Aerogels's cash & equivalents decreased by 9.5% year-over-year, from $167.62M to $151.71M.
- What is the long-term trend for Aspen Aerogels's cash & equivalents?
- Over 5 years (2020 to 2025), Aspen Aerogels's cash & equivalents has grown at a 56.9% compound annual growth rate (CAGR), from $16.5M to $156.86M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Aspen Aerogels's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude